Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms

<p>Evaluation of co-inhibitory molecules by patient response. Total T cells at screening and C1D15 were identified as being CD4+ or CD8+ and patients were grouped by best clinical response as partial response (PR) or non-PR. The percentage of each T cell subset expressing (A) PD-1, (B) LAG3, (...

पूर्ण विवरण

में बचाया:

ग्रंथसूची विवरण
मुख्य लेखक:	Dwight H. Owen (15034782) (author)
अन्य लेखक:	Brooke Benner (15054338) (author), Lai Wei (15023852) (author), Vineeth Sukrithan (15054341) (author), Ashima Goyal (15054344) (author), Ye Zhou (15054347) (author), Carly Pilcher (15054350) (author), Sheryl-Ann Suffren (15054353) (author), Gwen Christenson (15054356) (author), Nancy Curtis (15054359) (author), Megan Jukich (15054362) (author), Emily Schwarz (15054365) (author), Himanshu Savardekar (15054368) (author), Ruthann Norman (15054371) (author), Sarah Ferguson (15054374) (author), Barbara Kleiber (15054377) (author), Robert Wesolowski (8863505) (author), William E. Carson (15054380) (author), Gregory A. Otterson (15054383) (author), Claire F. Verschraegen (15054386) (author), Manisha H. Shah (15054389) (author), Bhavana Konda (15054392) (author)
प्रकाशित:	2025
विषय:	Cancer Therapeutic Research and Development Immuno-oncology Clinical Research and Trials Chemotherapy Combination chemotherapy Clinical Trial Results Phase II clinical trials Endocrine-Related Cancers Immunotherapy Checkpoint blockade Lung Cancer
टैग:	टैग जोड़ें कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
द्वारा: Dwight H. Owen (15034782)
प्रकाशित: (2025)

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
द्वारा: Dwight H. Owen (15034782)
प्रकाशित: (2025)

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
द्वारा: Dwight H. Owen (15034782)
प्रकाशित: (2025)

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
द्वारा: Dwight H. Owen (15034782)
प्रकाशित: (2025)

Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
द्वारा: John A. Ligon (15024477)
प्रकाशित: (2025)

Supplementary Figure S1 from First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti–PD-L1 Antibody ZKAB001
द्वारा: Yan Zhou (15053225)
प्रकाशित: (2025)

Supplementary Figure S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
द्वारा: Aurelius Omlin (14971513)
प्रकाशित: (2025)

Supplementary Table S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
द्वारा: Aurelius Omlin (14971513)
प्रकाशित: (2025)

Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
द्वारा: Chong Kin Liam (15331321)
प्रकाशित: (2025)

Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
द्वारा: Chong Kin Liam (15331321)
प्रकाशित: (2025)

Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
द्वारा: Chong Kin Liam (15331321)
प्रकाशित: (2025)

Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
द्वारा: Chong Kin Liam (15331321)
प्रकाशित: (2025)

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
द्वारा: Qingsheng Xu (17078830)
प्रकाशित: (2025)

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
द्वारा: Qingsheng Xu (17078830)
प्रकाशित: (2025)

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
द्वारा: Ulka N. Vaishampayan (15051039)
प्रकाशित: (2025)

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
द्वारा: Ulka N. Vaishampayan (15051039)
प्रकाशित: (2025)

Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
द्वारा: Ulka N. Vaishampayan (15051039)
प्रकाशित: (2025)

Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
द्वारा: Ulka N. Vaishampayan (15051039)
प्रकाशित: (2025)

Supplementary Figure 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
द्वारा: Tom Wei-Wu Chen (15053003)
प्रकाशित: (2025)

Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
द्वारा: Tom Wei-Wu Chen (15053003)
प्रकाशित: (2025)

Supplementary Figure 3 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
द्वारा: Tom Wei-Wu Chen (15053003)
प्रकाशित: (2025)

Supplementary Figure 4 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
द्वारा: Tom Wei-Wu Chen (15053003)
प्रकाशित: (2025)

Supplementary Table 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
द्वारा: Tom Wei-Wu Chen (15053003)
प्रकाशित: (2025)

Supplementary Figure S1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
द्वारा: Fabrice Barlesi (15045504)
प्रकाशित: (2025)

Supplementary Figure S2 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
द्वारा: Fabrice Barlesi (15045504)
प्रकाशित: (2025)

Supplementary Figure S3 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
द्वारा: Fabrice Barlesi (15045504)
प्रकाशित: (2025)

Supplementary Figure S4 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
द्वारा: Fabrice Barlesi (15045504)
प्रकाशित: (2025)

Supplementary Figure S5 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
द्वारा: Fabrice Barlesi (15045504)
प्रकाशित: (2025)

Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder
द्वारा: Roger Li (17078665)
प्रकाशित: (2025)

Supplementary Figure 1 from Randomized Phase II Study of Physiologic MRI-Directed Adaptive Radiation Boost in Poor Prognosis Head and Neck Cancer
द्वारा: Michelle L. Mierzwa (14963463)
प्रकाशित: (2025)

Supplementary Figures S1-S4 from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial
द्वारा: Giuseppe Basile (15051269)
प्रकाशित: (2025)

Supplementary Table S4 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
द्वारा: Andrés Elía (15055031)
प्रकाशित: (2025)

Supplementary Table S5 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
द्वारा: Andrés Elía (15055031)
प्रकाशित: (2025)

Supplementary Table S6 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
द्वारा: Andrés Elía (15055031)
प्रकाशित: (2025)

Supplementary Table S7 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
द्वारा: Andrés Elía (15055031)
प्रकाशित: (2025)

Supplementary Table S8 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
द्वारा: Andrés Elía (15055031)
प्रकाशित: (2025)

Figure 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
द्वारा: Nigel Bundred (15046233)
प्रकाशित: (2025)

Figure 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
द्वारा: Nigel Bundred (15046233)
प्रकाशित: (2025)

Figure 3 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
द्वारा: Nigel Bundred (15046233)
प्रकाशित: (2025)

Table 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
द्वारा: Nigel Bundred (15046233)
प्रकाशित: (2025)

Cannot write session to /tmp/vufind_sessions/sess_5505gepak0aovp89q56pl4bbtc